Concordia Healthcare Corp. to host third quarter 2014 results conference call

TORONTO, Oct. 23, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (TSX: CXR) (OTCQX: CHEHF), today announced it will release its third quarter 2014 financial results after market close on Thursday, November 13, 2014. The Company will subsequently hold a conference call on Friday, November 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, Mr. Leith Tessy, Chief Financial Officer, and Mr. Wayne Kreppner, Chief Operating Officer. A question-and-answer session will follow the corporate update.

This call is being webcast and can be accessed from the Concordia website at www.concordiarx.com. An archived replay of the webcast will be available for one year.

About Concordia
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The Company's pharmaceutical business consists of ADHD-treatment Kapvay® (clonidine extended release tablets), head lice treatment Ulesfia® (benzyl alcohol) Lotion, asthma-related medication Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets), seizure medication Zonegran (zonisamide), and irritable bowel syndrome treatment Donnatal® (belladonna alkaloids, phenobarbital). Concordia's Specialty Healthcare Distribution (SHD) division, Complete Medical Homecare, distributes medical supplies targeting diabetes and related conditions. Concordia's orphan drug division, Pinnacle, markets PHOTOFRIN® in the United States.

Concordia operates out of facilities in Oakville, Ontario; Lenexa, Kansas (near Kansas City, Missouri); Chicago, Illinois; Bridgetown, Barbados; and Charlottesville, Virginia.

SOURCE Concordia Healthcare Corp.